National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

NCPE Assessment Process Complete
Rapid review commissioned 26/09/2018
Rapid review completed 11/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 17/10/2018
Pre-submission consultation with Applicant 05/11/2018
Submission received from Applicant 14/01/2019
Preliminary review sent to Applicant 18/01/2019
Current status Awaiting response from Applicant